🔗 Share this article

An underground economy for unapproved weight-loss drugs is propelled by social media fitness personalities and sellers on messaging platforms, based on recent findings.

Experimental Drug Gaining Popularity Via Social Media

Retatrutide, which is still in research studies, is being advertised by social media influencers for its alleged fat-burning properties. Followers are encouraged to message these accounts privately for supplier links, while also receiving discount codes.

Thriving Trade on Messaging Platforms

Additionally, a flourishing trade exists on messaging services, where groups with numerous of members share “before and after” photos, injection guides and claims of next-day UK delivery. Vendors promote the drug there before redirecting customers to other platforms for purchases.

Understanding The Experimental Drug

Retatrutide is an experimental injectable developed by American pharmaceutical company Eli Lilly. The drug targets three gut hormones – GLP-1, GIP and glucagon. Early trials suggest it could help patients reduce up to 25% of their total weight. Nicknamed the “triple G”, the drug is being hailed digitally as the next Ozempic.

Medical Experts Express Concerns

Nevertheless, doctors and pharmacists have warned that the sale of what remains an unapproved drug in the United Kingdom is a cause for concern and could result in users administering substances of unknown origin.

Some professionals said the popularity for retatrutide could be connected to the rising cost of approved slimming products such as Mounjaro.

Regulatory Status and Enforcement

Marketing the unapproved drug on social media or Telegram is prohibited in the UK, as it is an unapproved drug that must not be promoted or supplied for personal consumption under the Human Medicines Regulations 2012.

Some content creators try to circumvent the rules by calling to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled drug, but promotion and distribution can still violate pharmaceutical, marketing, and customer laws, potentially leading to fines, prosecution or imprisonment.

Platform Response and Material Removal

Based on the social media company, the platform has taken down violative material and prohibited associated keywords and search suggestions. The company stated it was committed to maintaining the platform secure and allocating resources in strengthening enforcement strategies.

Online Trading Operations

Research also found groups with up to 9,000 participants selling retatrutide using the platform's built-in search feature, which functions like a online catalog. Typing “retatrutide” immediately displays groups with numerous of members, filled with images of slimming results, positive reviews and detailed guides for preparing or administering at residence.

After moments of entering one group, a vendor posted WhatsApp details, where most transactions take place. The vendor provided an instruction manual and guaranteed delivery within two days. When questioned whether the substance was authentic, one seller responded: “You can’t be sure.” Another provided a photo of a alleged laboratory certificate. Not one asked about weight, medical conditions or previous experience.

Product Details and Costs

Within these groups, posts display black plastic parcels with Royal Mail stickers, claiming to include new batches. One communication stated: “It took eight of us to load them this morning.”

Buyers can choose between powder vials, mixed at residence with purified liquid, or ready-to-use injectors usually sold at £160 for 20mg. When questioned how long a pen should be used, sellers give contradictory responses ranging from a several days to “depends on your body”.

Platform Moderation and Safety Measures

A representative for the messaging service stated it actively monitored harmful material on its platform including material that promoted the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Warnings

“People are administering materials they can’t verify. Even if the research behind retatrutide is sound, these digital versions may not contain what they advertise,” stated a pharmacy expert, the director of pharmaceutical services at Chemist4U.

A medical professional of Asda Online Doctor linked the increase in demand to recent price rises for authorized slimming drugs such as Mounjaro. “With prices rising, patients are turning to online platforms. But counterfeit treatments are highly risky. You cannot know what’s inside or whether the conditions they were produced in was sterile,” she explained.

Her staff has previously seen patients harmed by self-injection from unverified sources. “We understand the frustration, but purchasing from Telegram or WhatsApp is gambling with your well-being,” stated Wyllie. “These materials could be contaminated or improperly measured.”

Manufacturer Position

A representative from Eli Lilly said the substance was in phase 3 research studies and had not been reviewed or approved by any government authority anywhere in the world. “Therefore at this point no one can market [it] for personal consumption,” they said, noting that any item “misleadingly claiming itself as a company investigational product not yet authorized … may subject patients to potentially serious health risks”.